Aristea Therapeutics to Present at Upcoming Investor ConferencesSeptember 20, 2021
SAN DIEGO, Sept. 20, 2021 /PRNewswire/ — Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat rare serious inflammatory diseases, today announced that James Mackay, Ph.D., President and CEO, will participate in the following investor conferences in September and October:
UBS Private Company Conference
Date: September 22, 2021
Time: 10:30 a.m. PT
Cantor Fitzgerald Healthcare Conference
Date: September 29, 2021
Time: 1 p.m. PT
Needham Biotech Private Company 1×1 Forum
Date: October 19-20, 2021
Archived versions of the virtual presentations/fire-side chats will be available through the Aristea website at www.aristeatx.com following the conferences.
About Aristea Therapeutics
Aristea Therapeutics (Air-iss-tay-uh) is a clinical-stage immunology focused drug development company developing novel therapies to treat rare serious inflammatory diseases. The Aristea team is leveraging its broad industry expertise and proven success in drug development to form synergistic partnerships and build a pipeline of novel drugs. Aristea’s lead program, RIST4721, is currently in Phase 2b clinical development. Aristea is headquartered in San Diego, CA.
To learn more, please visit www.aristeatx.com and follow us on social media @Aristeatx
For media inquiries contact:
David Schull or Ignacio Guerrero-Ros, Ph.D.